Fujisawa Pharmaceutical Company, Ltd.

Masanori Okamoto

Shigehiro Takase

Masakuni Okuhara

Hiroshi Imanaka

Hiroshi Hatanaka

Eisaku Tsujii

Masanobu Kohsaka

Itsuo Uchida

Nobuharu Shigematsu

Kazuyoshi Umehara

Masami Ezaki

Morita Iwami

Hirokazu Tanaka

Yasuhisa Tsurumi

Tsutomu Kaizu

Masashi Hashimoto

Teruo Kyoto Oku

Hiroshi Kayakiri

Satoshi Okada

Kozo Sawada

Hatsuo Aoki

Katsuya Nakamura

Eiko Iguchi

Keizo Yoshida

Naoki Fukami

Yoshiko Yokota

Toshio Hattori

Kiyoshi Takatsuki

Takashi Fujita

Takanao Otsuka

Keiji Hemmi, Deceased

Kunio Nakahara

Masanobu Konsaka

Yohsuke Maeda

Yoshitada Notsu

Yasuhiko Shinguh

Seiji Yoshimura

Noriaki Inamura

Amino acid derivatives and their use as phospholipase A.sub.2 inhibitor

FR901451 substance, process for preparation thereof and use thereof

A degenerative disease selected from the group consisting of cystic fibrosis, chronic bronchitis and bronchiectasia is treated by administering to a subject a therapeutically effective amount of WS7622A mono-or disulfate or pharmaceutically acceptable salt thereof.

WS7622A mono- or di-sulfate, process for preparation thereof and use

WS7622A mono- or di-sulfate and pharmaceutically acceptable salts thereof. WS7622A exhibits human leukocyte elastase-inhibiting activity.

WS7622A mono- or di- sulfate, process for preparation thereof and use

A method for therapy of disseminated intravascular coagulation, or chronic respiratory tract infectious disease characterized by administering to a patient in need thereof an effective dose suitable for therapeutic treatment of said condition of WS7622A mono- or di-sulfate ester or their pharmaceutically acceptable salt.

Prophylactic/therapeutic composition for disseminated intravascular

A method of treating pulmonary emphysema or adult respiratory distress syndrome in a subject in need thereof which comprises administering to the subject an effective amount of WS7622A, B, C and/or D, derivatives thereof, or their pharmaceutically acceptable salt.

WS7622A, B, C and D substances, derivatives thereof, processes for

Pyrroline compounds of the formulae (I) and (II) are effective in the treatment of retroviral infection and lymphadenopathy. ##STR1##

Antiretroviral agent, method of use thereas, and method of preparation

A compound of the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are each lower alkyl, R.sup.4 is hydrogen or hydroxy, and a heavy solid line means a double bond when R.sup.4 is hydrogen and a single bond when R.sup.4 is hydroxy is useful in the treatment of diseases caused by reactive oxygen species and organic radicals.

Pharmaceutically useful 5-hydroxy-2,3-dihydro-benzofurans and

The present invention relates to new WS7622A, B, C and/or D substances, derivatives thereof and pharmaceutical compositions containing the new substances as active ingredients.

The invention relates to a compound of antimicrobial activity of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkanoyl,

Compound, WF11605 and derivative thereof

New nitro aliphatic compounds useful as antithrombotic and antihypertensing agents are disclosed.

Nitro aliphatic compounds, process for preparation thereof and use

The invention relates to novel furanone derivatives, having an aldose reductase-inhibitory activity, of the formula ##STR1## wherein A is a lower alkylene group,

Furanone derivatives, process for preparation thereof and use thereof

The invention relates to compounds of antihypertensive and antithrombotic activity of the formula or its pharmaceutically acceptable salt: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, or lower alkoxyphenyl,

Nitro aliphatic compounds and use thereof

New nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

New Nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

Growing community of inventors

Tsukuba, Japan

Masanori Okamoto